Therapeutic efficacy of bevacizumab for age-related macular degeneration: What are the implications of CATT for routine management?

Drugs and Aging

Volumn 28, Issue 11, 2011, Pages 853-865

  Ziemssen, Focke ^a   Sobolewska, Bianka ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Elderly; Ranibizumab; Vascular endothelial growth factor inhibitors

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; CLINICAL PROTOCOL; CONTROLLED STUDY; COUNSELING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; COSTS AND COST ANALYSIS; COUNSELING; HUMANS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 80755126037     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11594720-000000000-00000     Document Type: Review

References (65)

1. Ziemssen F, Heiduschka P, Schraermeyer U. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2007; 27 (8): 1154-6
2. Martin DF, Maguire MG, Fine SL. Identifying and elim-inating the roadblocks to comparative-effectiveness research. N Engl J Med 2010; 363: 105-7
3. The CATT Research Group. Ranibizumab and beva-cizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908
4. American Academy of Ophthalmology. Statement from the American Academy of Ophthalmology regarding the results of the Comparison of AMD Treatment Trials [press release]. 2011 Apr 28 [online]. Available from URL: http://www. aao.org/newsroom/release/20110428.cfm [Accessed 2011 Sep 12]
5. The Royal College of Ophthalmologists. Press statement on the CATT study [press release]. 2011 Apr 5 [online]. Available from URL:http://www.rcophth.ac. uk/news.asp?itemid= 427&itemTitle=Press+Statement+on+the+CATT+Study& section=24§ionTitle=News [Accessed 2011 Sep 12]
6. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmaco-therapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file. Am J Ophthalmol 2011; 151 (5): 887-895.e1
7. Ziemssen F, Grisanti S, Bartz-Schmidt KU, et al. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 2009; 26 (4): 295-320
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44 (Pubitemid 44511558)
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31 (Pubitemid 44511557)
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovas-cular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58
11. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2011 May; 118: 831-9
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13
13. Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol 2011 May; 249: 631-2
14. Muether PS, Hermann MM, Koch K, et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011; 249: 633-7
15. Boron WF. NIH funding of the independent investigator. Physiology 2006; 21: 300-1 (Pubitemid 44511757)
16. Shekelle P. Pharmaceutical company-sponsored drug trials: what are we to believe? J Clin Epidemiol 2010; 63: 126-7
17. Lichter PR. Continuing medical education, physicians, and Pavlov: can we change what happens when industry rings the bell? Arch Ophthalmol 2008; 126: 1593-7
18. Novack GD. The role of pharmaceutical companies in sponsored research. Ophthalmology 2007; 114: 1037-8 (Pubitemid 46829386)
19. Jampol LM, Packer S, Mills RP, et al. A perspective on commercial relationships between ophthalmology and industry. Arch Ophthalmol 2009; 127: 1194-202
20. Miller LE, Stewart ME. The blind leading the blind: use and misuse of blinding in randomized controlled trials. Con-temp Clin Trials 2011; 32: 240-3
21. Eriksson U, Alm A, Larsson E. Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration? Acta Ophthalmol. Epub 2011 Mar 4: doi: 10.1111/j.1755-3768.2011. 02112.x
22. Querques G, Forte R, Berboucha E, et al. Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res 2011 Mar 8; 46 (3): 152-9
23. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascu-larization. Ophthalmology 2010; 117: 1376-80
24. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal, and sub-pigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011; 52: 1599-605
25. Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye (Lond) 2011 Aug; 25 (8): 1034-8
26. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010; 150: 666-73
27. Zhao W, Weng Y, Wu Q, et al. Quantitative comparison of randomization designs in sequential clinical trials based on treatment balance and allocation randomness. Pharm Stat. Epub 2011 May 5: doi: 10.1002/pst.493
28. Chylack Jr LT, Wolfe JK, Singer DM, et al. The Lens Opa-cities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993; 111: 831-6 (Pubitemid 23170599)
29. Fleming TR. Addressing missing data in clinical trials. Ann Intern Med 2011 Jan 18; 154 (2): 113-7
30. Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med 2000; 1: 19-21 (Pubitemid 32219869)
31. Johanson R, Burr R, Leighton N, et al. Informed choice? Evidence of the persuasive power of professionals. J Public Health Med 2000; 22: 439-40
32. Tarn DM, Paterniti DA, Heritage J, et al. Physician commu-nication about the cost and acquisition of newly prescribed medications. Am J Manag Care 2006 Nov; 12 (11): 657-64 (Pubitemid 44748392)
33. Edwards M, Davies M, Edwards A. What are the external influences on information exchange and shared decision-making in healthcare consultations: a meta-synthesis of the literature. Patient Educ Couns 2009 Apr; 75 (1): 37-52
34. Tarn DM, Paterniti DA, Williams BR, et al. Which provi-ders should communicate which critical information about a new medication? Patient, pharmacist, and physician perspectives. J Am Geriatr Soc 2009 Mar; 57 (3): 462-9
35. Goff SL, Mazor KM, Meterko V, et al. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med 2008 Mar; 23 (3): 236-41
36. Swindell JS, McGuire AL, Halpern SD. Beneficent persua-sion: techniques and ethical guidelines to improve patients' decisions. Ann Fam Med 2010; 8: 260-4
37. Keane PA, Patel PJ, Ouyang Y, et al. Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2010 Nov; 51 (11): 5431-7
38. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010 Apr; 117 (4): 747-56.e4
39. Yu L, Liang XH, Ferrara N. Comparing protein VEGF in-hibitors: in vitro biological studies. Biochem Biophys Res Commun 2011 May 6; 408 (2): 276-81
40. Deissler HL, Deissler H, Lang GE. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction inducedbygrowth factors in microvascular retinal endothelial cells. Br J Ophthalmol 2011 Aug; 95 (8): 1151-6
41. Campbell RJ, Bronskill SE, Bell CM, et al. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010 Mar; 128: 359-62
42. Ferrara N, Damico L, Shams N, et al. Development of ra-nibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26 (8): 859-70 (Pubitemid 44547437)
43. Genentech. Genentech statement on CAT trial data published in the New England Journal of Medicine [press release]. 2011 Apr 28 [online]. Available from URL: http://www.gene.com/gene/news/press-releases/press-statements/ps- 042811.html [Accessed 2011 Sep 13]
44. Ziemssen F, Bartz-Schmidt KU, Grisanti S. (Side) effects of VEGF inhibition. Ophthalmologe 2006; 103 (6): 484-92 (Pubitemid 43892187)
45. US Social Security Administration. Period life table, 2007 [online]. Available from URL: http://www.ssa.gov/oact/STATS/table4c6.html [Accessed 2011 Sep 13]
46. Ezzati M, Friedman AB, Kulkarni SC, et al. The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States. PLoS Med 2008 Apr 22; 5 (4): e66
47. Mitchell P. A systematic review of the efficacy and safety out-comes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011; 27 (7): 1465-75
48. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal beva-cizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011; 95 (3): 308-17
49. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56 (2): 95-113
50. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128 (10): 1273-9
51. Gower EW, Cassard S, Chu L, et al. Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration. Invest Oph-thalmol Vis Sci 2011; 52: E-Abstract 6644
52. Csaky K, Do DV. Safety implications of vascular en-dothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009 Nov; 148 (5): 647-56
53. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115 (10): 1750-5
54. Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye 2011; 25 (6): 710-6
55. Klettner AK, Kruse ML, Meyer T, et al. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Oph-thalmol 2009; 247: 1601-8
56. Klettner A, Mohle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 2010; 248: 819-24
57. Hawkes N. Cheap drug is as good at treating eye disorder as more expensive product, trial shows. BMJ 2011 May 3; 342: d2794
58. la Cour M. Intravitreal VEGF-inhibitors: is Avastin a gen-eric substitute for Lucentis? Acta Ophthalmol Scand 2007; 85 (1): 2-4
59. Patel JJ, Mendes MA, Bounthavong M, et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovas-cular age-related macular degeneration using a Markov model. J Eval Clin Pract. Epub 2010 Sep 16: doi: 10.1111/j.1365-2753.2010.01546.x
60. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91 (9): 1244-6 (Pubitemid 47344908)
61. Gower EW, Cassard SD, Bass EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 2010 Feb; 30 (2): 212-21
62. Neubauer AS, Holz FG, Sauer S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system. Clin Ther 2010 Jul; 32 (7): 1343-56
63. Mitchell P, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011 Feb 1; 29 (2): 107-31
64. Hodge W, Brown A, Kymes S, et al. Pharmacologic man-agement of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 2010; 45: 223-30
65. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008 May; 92 (5): 667-8 (Pubitemid 351684178)